DBV Technologies SA – (NASDAQ:DBVT) was the target of some unusual options trading activity on Tuesday. Investors acquired 354 put options on the stock. This is an increase of approximately 608% compared to the average volume of 50 put options.
DBV Technologies (DBVT) traded up $5.37 during trading hours on Wednesday, reaching $26.23. 3,517,380 shares of the company’s stock traded hands, compared to its average volume of 292,696. DBV Technologies has a 52-week low of $20.08 and a 52-week high of $50.57.
Large investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in DBV Technologies in the 3rd quarter valued at about $2,190,000. Citadel Advisors LLC purchased a new stake in DBV Technologies in the 3rd quarter valued at about $7,794,000. Sabby Management LLC purchased a new stake in DBV Technologies in the 2nd quarter valued at about $1,339,000. Dynamic Technology Lab Private Ltd increased its stake in DBV Technologies by 87.6% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock valued at $495,000 after buying an additional 5,441 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in DBV Technologies by 10.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,797,789 shares of the company’s stock valued at $118,738,000 after buying an additional 257,210 shares during the last quarter. Hedge funds and other institutional investors own 46.36% of the company’s stock.
WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/dbv-technologies-target-of-unusually-high-options-trading-dbvt.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.